Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.7K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.7K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

3.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PRDM16 modulates aspects of cell cycle dynamics and maturation in human iPSC-derived cardiomyocytes.

Stem cell reports·2026
Same author

iPSC-derived modeling of HLA-lacking hematopoiesis reveals clonal diversity in eltrombopag response in acquired aplastic anemia.

Stem cells (Dayton, Ohio)·2026
Same author

NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.

Leukemia·2026
Same author

Impact of Pulmonary Vein Morphology on the Number of Pulsed Field Ablation Applications Using Circular Multielectrode Catheters.

Journal of cardiovascular electrophysiology·2025
Same author

Integrative Transcriptomic-Histological Analysis in Dilated Cardiomyopathy Unveils FGFR1 Inhibition as Anti-Cardiac Fibrotic and Cardioprotective Therapy.

JACC. Basic to translational science·2025
Same author

Generation of mature epicardium derived from human-induced pluripotent stem cells via inhibition of mTOR signaling.

Nature communications·2025

Related Experiment Video

Updated: May 7, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.2K

[Drug discovery using iPS cells and in silico model].

Yuya Fujiwara1, Yoshinori Yoshida1

  • 1Center for iPS Cells Research and Application, Kyoto University.

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|January 5, 2025
PubMed
Summary

Human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CMs) are vital for cardiovascular disease research. This review explores their use in drug discovery and regenerative medicine, alongside challenges and the role of in silico models.

More Related Videos

In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes
11:42

In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes

Published on: June 10, 2021

4.8K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

2.7K

Related Experiment Videos

Last Updated: May 7, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.2K
In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes
11:42

In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes

Published on: June 10, 2021

4.8K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

2.7K

Area of Science:

  • Cardiovascular Research
  • Stem Cell Biology
  • Drug Discovery
  • Regenerative Medicine

Background:

  • Human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CMs) model human cardiomyocyte properties and disease phenotypes.
  • hiPSC-CMs are crucial for developing cardiovascular therapeutics and regenerative medicine, offering an alternative to heart transplantation.
  • Organoid models enhance in vitro replication of complex heart tissue structures, aiding drug discovery.

Purpose of the Study:

  • To review the current status and challenges of drug discovery utilizing hiPSC-CMs.
  • To examine the integration and impact of in silico models (AI and simulations) in hiPSC-CM based drug discovery.
  • To identify limitations in current hiPSC-CM applications for drug efficacy prediction and regenerative medicine safety.

Main Methods:

  • Review of published reports on hiPSC-CMs in drug discovery and regenerative medicine.
  • Analysis of current limitations in quantifying hiPSC-CM characteristics and predicting drug outcomes.
  • Exploration of in silico approaches, including artificial intelligence (AI) and simulations, for phenotype scoring and risk prediction.

Main Results:

  • hiPSC-CMs offer significant potential for disease modeling and therapeutic development in cardiovascular medicine.
  • Current drug discovery methods using hiPSC-CMs face challenges in quantitative analysis and clinical prediction.
  • In silico models are emerging as valuable tools for enhancing phenotype assessment and risk prediction in hiPSC-CM research.

Conclusions:

  • hiPSC-CMs and advanced in silico models represent a promising frontier for cardiovascular drug discovery and regenerative medicine.
  • Addressing current limitations in quantification, quality control, and safety verification is essential for clinical translation.
  • Continued development and integration of AI and simulation technologies will accelerate therapeutic advancements.